MedTrace Logo

Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)

NCT04464122 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2025-04-03

No results posted yet for this study

Summary

This is a multicentre, controlled, observational prospective study on new biomarkers, as immune profiling, angiogenetic markers and circRNA from TEPs in the diagnosis and in the evaluation of treatment response in pulmonary and gastro-entero-pancreatic NENs.

Conditions

  • Neuroendocrine Tumors
  • Neuroendocrine Neoplasm
  • Neuroendocrine Tumor Grade 1
  • Neuroendocrine Tumor Grade 2
  • Neuroendocrine Carcinoma

Interventions

DRUG

Somatostatin analog; chemotherapy

According to current ENETS guidelines, patients will be treated by somatostatin analogs or chemotherapy, recommended respectively as first line therapy in neuroendocrine tumours or neuroendocrine neoplasms.

Sponsors & Collaborators

  • University of Roma La Sapienza

    lead OTHER

Principal Investigators

  • Andrea M Isidori, MD, PhD · Department of Experimental Medicine, Sapienza University of Rome

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-14
Primary Completion
2025-09-14
Completion
2025-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04464122 on ClinicalTrials.gov